Drugs / SHR-3032
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06090799 | Nov 2023 → Mar 2024 | disease related to solid organ transplantation | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-3032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06090799 ↗ |
| Route | Intravenous | “Following Single Intravenous Administration” NCT06090799 ↗ |